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Introduction
Mammalian platelets are small anucleated blood cells special-
ized to continuously monitor and preserve the integrity of the 
cardiovascular system (hemostasis) (1–3). Once released from 
megakaryocytes, they circulate for 10 days in human blood and 5 
days in mouse blood. If they are not consumed in the hemostatic 
process, senescent platelets are destroyed by the reticuloendothe-
lial system in the spleen and the liver (4). Thrombus formation at 
sites of vascular injury depends on a high sensitivity of platelets 
toward agonists and the ability to shift from an antiadhesive to a 
proadhesive state. Aberrant platelet activation, however, can lead 
to premature platelet clearance or the formation of intravascular 
occlusive thrombi (thrombosis), as seen in myocardial infarction 
(heart attack) and ischemic stroke (1). Thus, platelet activation 
needs to be tightly regulated to facilitate vascular hemostasis and 
to prevent thrombocytopenia and thrombosis. Inhibitors of the 
purinergic receptor, P2Y12, are used widely to prevent throm-
botic complications in patients with cardiovascular disease. Early 
studies demonstrated that P2Y12 mediates the amplifying effects 
of adenosine diphosphate (ADP) on platelet activation by various 
agonists (5, 6). Engagement of P2Y12 has been linked to several 
downstream signaling events, including inhibition of adenylate 
cyclase (7, 8) and activation of phosphoinositide 3-kinase (PI3K) 
(9), the serine/threonine PKB/AKT (10), and the small GTPase 
RAS-related protein 1 (RAP1) (11–13).
RAP proteins are small GTPases of the RAS family, which are 
expressed in various cell types, including endothelial cells, leuko-
cytes, and platelets (14). The RAP family includes 5 members that 
are grouped into 2 subfamilies, RAP1 and RAP2. Small GTPases 
cycle between an inactive GDP-bound form and an active GTP-
bound form. They are regulated tightly by GEFs, which stimu-
late GTP loading, and GAPs, which catalyze GTP hydrolysis. Our 
recent work and that of others demonstrated that RAP1 is a central 
signaling node, regulating platelet adhesion and thrombosis (15–
17), and that CalDAG-GEFI (also known as RASGRP2) is a critical 
RAP-GEF expressed in platelets (18–21). Upon cellular stimula-
tion, CalDAG-GEFI is important for the rapid, calcium-dependent 
(Ca2+-dependent) activation of RAP1 and integrin αIIbβ3 (22–26). 
RAP1 activation in the absence of Ca2+/CalDAG-GEFI is compar-
atively slow but sustained (17) and requires signaling via PKC (23, 
27), P2Y12 (11, 13, 17), and PI3K (11, 28).
The small GTPase RAP1 is critical for platelet activation and thrombus formation. RAP1 activity in platelets is controlled by 
the GEF CalDAG-GEFI and an unknown regulator that operates downstream of the adenosine diphosphate (ADP) receptor, 
P2Y12, a target of antithrombotic therapy. Here, we provide evidence that the GAP, RASA3, inhibits platelet activation and 
provides a link between P2Y12 and activation of the RAP1 signaling pathway. In mice, reduced expression of RASA3 led to 
premature platelet activation and markedly reduced the life span of circulating platelets. The increased platelet turnover 
and the resulting thrombocytopenia were reversed by concomitant deletion of the gene encoding CalDAG-GEFI. Rasa3 
mutant platelets were hyperresponsive to agonist stimulation, both in vitro and in vivo. Moreover, activation of Rasa3 
mutant platelets occurred independently of ADP feedback signaling and was insensitive to inhibitors of P2Y12 or PI3 kinase. 
Together, our results indicate that RASA3 ensures that circulating platelets remain quiescent by restraining CalDAG-GEFI/
RAP1 signaling and suggest that P2Y12 signaling is required to inhibit RASA3 and enable sustained RAP1-dependent platelet 
activation and thrombus formation at sites of vascular injury. These findings provide insight into the antithrombotic effect of 
P2Y12 inhibitors and may lead to improved diagnosis and treatment of platelet-related disorders.
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However, we consistently observed a more severe hemorrhagic 
phenotype in Rasa3–/– embryos when compared with Rasa3fl/flPF4-
Cre+ embryos, suggesting that RASA3-expressing cells other than 
platelets also contribute to vascular integrity in the developing 
mouse embryo. While characterizing these knockout mice, we 
also identified a recessive Rasa3 allele causing a missense muta-
tion (H794L) in another thrombocytopenic mouse strain, hlb381 
(Rasa3hlb), derived from a forward genetic screen in C57BL/6J 
mice (Supplemental Figure 1C). Rasa3hlb/hlb mice were born at 
expected Mendelian ratios (data not shown), and their peripheral 
platelet counts were significantly higher than those observed in 
Rasa3 knockout mice or mice with a different missense mutation 
in Rasa3 (i.e., Rasa3scat mice) (Figure 2A, Supplemental Figure 3, 
and ref. 33). Platelets in Rasa3hlb/hlb mice were larger in size (Supple-
mental Figure 4 and Table 1). wbc counts in Rasa3hlb/hlb mice were 
also significantly decreased, while their rbc counts and hematocrit 
were normal (Table 1). Platelet and leukocyte counts were normal 
in Rasa3+/hlb mice as well as Rasa3+/scat mice (ref. 33 and Table 1). 
Severe thrombocytopenia, however, was observed in compound 
heterozygous Rasa3hlb/scat mice (Supplemental Figure 3), confirm-
ing that the mutations in Rasa3 are causative for the low peripheral 
platelet counts observed in Rasa3scat and Rasa3hlb homozygotes. 
Interestingly, RASA3 expression was reduced strongly in lysates 
from Rasa3hlb/hlb platelets when compared with WT cells (Figure 
2A). Furthermore, RASA3 expression in platelets from mice het-
erozygous for the H794L mutation (Rasa3+/hlb) was comparable to 
that in platelets from Rasa3+/– or Rasa3+/flPF4-Cre+ heterozygous 
mice (Supplemental Figure 5, A and B). Thus, our data strongly 
suggest that the H794L mutation markedly impairs expression or 
stability of RASA3 protein and that the very low level of expression 
explains the hypomorphic phenotype of Rasa3hlb/hlb mice. Consis-
tently, bioinformatics analyses using the SIFT, Panther, and Mut-
Pred algorithms predict that the RASA3(H794L) mutation is not 
tolerated among various species (40, 41).
The incomplete thrombocytopenia and the Mendelian birth 
rates observed in Rasa3hlb/hlb mice provided us with a unique model 
system to isolate Rasa3 mutant platelets for functional studies. 
Rasa3hlb/hlb platelets exhibited increased levels of activated RAP1 
(RAP1-GTP) and activated integrin αIIbβ3, both at baseline and 
in response to agonist stimulation (Figure 2B). Surface expression 
levels of αIIbβ3 were not significantly different between Rasa3hlb/hlb 
and control platelets (data not shown). Furthermore, the percent-
age of reticulated (young) platelets in the peripheral blood was 
markedly higher in Rasa3hlb/hlb mice (Figure 2C), suggesting that 
the thrombocytopenia in these mice may result from increased 
platelet clearance but not impaired platelet production. Consistent 
with this hypothesis, we observed a markedly reduced half-life 
for circulating Rasa3hlb/hlb platelets compared with that for Rasa3+/+ 
platelets (t1/2 ~14 hours and t1/2 ~55 hours, respectively) (Figure 2D). 
Severe thrombocytopenia (Figure 2E) and reduced platelet sur-
vival (data not shown) were also observed in lethally irradiated 
Rasa3+/+ mice reconstituted with bone marrow cells from Rasa3hlb/hlb 
mice, excluding the possibility that the increased clearance rate 
resulted from a hyperactive phagocytic system. Rasa3hlb/hlb mice 
displayed splenomegaly (Table 1), effacement of the splenic archi-
tecture (Supplemental Figure 6A), and a significant expansion of 
megakaryocytes in the red pulp (Figure 2F and Supplemental Fig-
Based on these differences in the kinetics of RAP1 activa-
tion, we proposed that the P2Y12 signaling axis leads to sustained 
activation of RAP1 and αIIbβ3 integrin by negatively regulating a 
putative RAP-GAP. In previous work, Smolenski and colleagues 
suggested a role for RAP1GAP2 in platelet activation (29). How-
ever, RNA and protein expression profiling demonstrated that 
RAP1GAP2 is very weakly expressed in human platelets and virtu-
ally absent in mouse platelets (30–32). The same studies identified 
the dual specificity GAP, RASA3, as the most abundant RAP-GAP 
expressed in platelets, with protein expression levels comparable 
to that of CalDAG-GEFI. An important confirmation that RASA3 
may be a critical regulator of platelet function came from our find-
ings that a G125V mutation in Rasa3 (Rasa3scat) is associated with 
severe thrombocytopenia in mice (33) and from recent studies 
by Molina-Ortiz et al., who described increased RAP1 activation 
in megakaryocytes from mice expressing a catalytically inactive 
mutant of RASA3 (34).
Here, we present evidence strongly suggesting that the GAP 
RASA3 (35) is the missing link between P2Y12 and RAP1 in plate-
lets and that inhibitors of P2Y12, used clinically, prevent throm-
bosis mainly via their effect on RASA3/RAP1 signaling. Our 
studies also demonstrate that mutations in RASA3 cause spon-
taneous platelet activation, CalDAG-GEFI/RAP1-dependent 
platelet clearance, and severe thrombocytopenia in mice, indi-
cating that RASA3 is critical for maintaining circulating platelets 
in a quiescent state.
Results
Platelet preactivation and increased platelet clearance in Rasa3 
mutant mice. In our search for novel RAP regulators in platelets, we 
identified RASA3 as the most abundant RAP-GAP based on recent 
transcriptomic and proteomic studies (30–32). Studies on the role 
of RASA3 in the activation response of human platelets are not 
possible currently, as specific inhibitors do not exist and patients 
with mutations in the gene have not been identified. Recent 
studies in mice demonstrated that expression of RASA3 mutants 
leads to high embryonic lethality and severe thrombocytopenia 
(33, 34). To test whether the embryonic lethality of Rasa3 mutant 
mice is caused by defective platelet function, we deleted Rasa3 
both systemically (Rasa3–/–) and specifically in the megakaryocyte 
lineage (Rasa3fl/flPF4-Cre+) (Supplemental Figure 1, A and B; sup-
plemental material available online with this article; doi:10.1172/
JCI77993DS1). Compared with their respective controls, both 
Rasa3–/– and Rasa3fl/flPF4-Cre+ mice exhibited high lethality at P21 
(Figure 1A). Peripheral platelet counts in embryos (data not shown) 
and in the few surviving Rasa3–/– mice (Figure 1B) were markedly 
decreased when compared with those of controls. Blood-filled 
lymphatic vessels were observed in Rasa3–/– and Rasa3fl/flPF4-Cre+ 
embryos but not Rasa3+/+ and Rasa3+/+PF4-Cre+ embryos (Figure 
1C). Immunohistochemistry studies confirmed the presence of 
rbc in lymphatic vessels of Rasa3–/– and Rasa3fl/flPF4-Cre+ embryos 
(Figure 1D), including cutaneous and jugular lymphatics and the 
thoracic duct (Supplemental Figure 2), in which platelets and the 
lymphovenous valve are required to prevent backflow of blood into 
the lymphatic vasculature (36). These findings are consistent with 
those of previous studies, demonstrating a critical role for platelets 
in lymphatic vascular development and survival of mice (37–39). 
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in the peripheral platelet count of Rasa3hlb/hlb mice (Figure 3A). 
Importantly, loss of CalDAG-GEFI also normalized the life span 
of Rasa3hlb/hlb platelets in circulation (Figure 3B). A significant 
increase in platelet life span and peripheral platelet counts was 
also observed in Rasa3scat/scat mice lacking CalDAG-GEFI (Supple-
mental Figure 7A). Platelets isolated from Caldaggef1–/– Rasa3scat/scat 
or Caldaggef1–/– Rasa3hlb/hlb mice did not show signs of preactivation 
of αIIbβ3 integrin (Supplemental Figure 7, B and C). Importantly, 
platelets isolated from Caldaggef1+/– Rasa3hlb/hlb mice had a signifi-
cantly shorter life span than control platelets when transfused into 
WT recipient mice (Figure 3C), confirming that the reduced plate-
let half-life observed in Rasa3 mutant mice is a platelet-intrinsic 
defect. Twenty-four hours after transfusion, increased numbers 
of Caldaggef1+/– Rasa3hlb/hlb platelets were detectable in the spleens 
and the livers of WT recipient mice (Supplemental Figure 8A). 
However, splenectomy did not lead to a recovery of the peripheral 
platelet count in Rasa3hlb/hlb mice (Supplemental Figure 8B).
Rasa3 mutant platelets are insensitive to inhibitors of P2Y12 and 
PI3K. Since RASA3 is critical to maintain circulating platelets in a 
resting state, we hypothesized that (a) RASA3 activity would be a 
limiting factor for platelet adhesion and hemostatic plug forma-
tion at sites of vascular injury and (b) RASA3 would be part of the 
ure 6B). Megakaryocyte numbers were also significantly higher in 
the bone marrow of Rasa3hlb/hlb mice (Figure 2G and Supplemen-
tal Figure 6B), but no other gross morphological changes were 
observed in bone sections when compared with those of controls 
(Supplemental Figure 6A). Rasa3hlb/hlb megakaryocytes stained pos-
itive for acetylcholinesterase (Supplemental Figure 6B), a marker 
for mature megakaryocytes (42), and exhibited an ultrastructure 
with a clear distinction between the perinuclear, intermediate, and 
ectoplasmic compartments (Supplemental Figure 6, C and D). No 
significant difference was observed in a CFU assay for megakary-
ocyte progenitors in bone marrow of Rasa3+/+ and Rasa3hlb/hlb mice 
(Figure 2H). Importantly, megakaryocytes isolated from Rasa3hlb/hlb 
mice were indistinguishable from Rasa3+/+ megakaryocytes in their 
ability to form proplatelets ex vivo (Figure 2I). Together, these data 
suggest increased platelet clearance as a major contributor to the 
thrombocytopenia observed in Rasa3hlb/hlb mice.
Loss of CalDAG-GEFI prolongs platelet life span and amelio-
rates thrombocytopenia in Rasa3 mutant mice. To test the hypoth-
esis that RASA3 restrains RAP1-dependent platelet activation and 
clearance, we crossed Rasa3hlb/hlb mice with CalDAG-GEFI knock-
out mice (resulting in Caldaggef1–/– Rasa3hlb/hlb mice). As shown in 
Figure 3, deletion of Caldaggef1 led to a dose-dependent increase 
Figure 1. Severe thrombocytopenia and embryonic lethality in Rasa3 knockout mice. (A) P21 survival of F1 generation offspring from crosses of Rasa3+/– 
or Rasa3+/flPF4-Cre+ mice. (B) Peripheral platelet count in Rasa3+/+ (n = 18), Rasa3+/– (n = 17), and Rasa3–/– (n = 2) mice. Due to the high mortality, statistical 
significance for the lower platelet counts observed in Rasa3–/– mice could not be established. (C and D) Severe thrombocytopenia in Rasa3 knockout ani-
mals results in a blood-lymphatic mixing phenotype during midgestation. (C) Representative images of Rasa3+/+ (E15.5), Rasa3–/– (E15.5), Rasa3+/+PF4-Cre+ 
(E17.5), and Rasa3fl/flPF4-Cre+ (E17.5) embryos showing hemorrhage (black arrows) and cutaneous blood-lymph mixing (blue arrowheads). The bottom row 
shows high-magnification images of the area around the eye. Scale bar: 1 mm (top row), 500 μm (bottom row). (D) Immunohistochemical analysis revealed 
the abnormal presence of rbc in the jugular lymph sac of Rasa3–/– and Rasa3fl/flPF4-Cre+ embryos. Sections were either stained with H&E (top rows) or with 
antibodies to LYVE-1 (green) and DAPI (blue) (bottom rows). Autofluorescent rbc (yellow) confirmed blood-filled lymphatic vessels. CA, carotid artery; JV, 
jugular vein; JLS, jugular lymph sac. Scale bar: 100 μm. Images in C and D are representative of 3 independent experiments.
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Notably, agonist-induced aggregation (Figure 5A) and RAP1 
activation (Figure 5B) were sensitive to inhibition of P2Y12 in 
Caldaggef1–/– platelets but not in Caldaggef1–/– Rasa3hlb/hlb platelets, 
even at threshold concentrations of agonists (Supplemental Figure 
9). Similarly P2Y12 inhibition had no significant effect on αIIbβ3 
activation in stimulated Caldaggef1–/– Rasa3scat/scat (Supplemen-
tal Figure 7B) or Caldaggef1–/– Rasa3hlb/hlb platelets (Supplemental 
Figure 7C). Signaling via P2Y12 leads to the activation of PI3K, 
and both RAP1 and the serine/threonine protein kinase AKT are 
known to be downstream of the P2Y12/PI3K signaling axis (10, 
13). We next evaluated whether PI3K signaling affects RAP1 acti-
vation in a RASA3-dependent manner. As expected, inhibition 
of PI3K by wortmannin inhibited RAP1 activation and αIIbβ3-
mediated aggregation of WT or Caldaggef1–/– platelets (Figure 5, 
A and B). However, saturating concentrations of PI3K inhibitors 
had little effect on the activation of RAP1 or αIIbβ3 in Caldaggef1–/– 
Rasa3hlb/hlb platelets. Importantly, inhibition of P2Y12 or PI3K abol-
ished AKT phosphorylation in Caldaggef1–/– Rasa3hlb/hlb and control 
platelets (Figure 5B). Thus, our studies suggest that RASA3 activ-
ity toward RAP1 is under the control of P2Y12 and PI3K, indepen-
dently of AKT. Impaired function of RASA3 leads to a state of con-
tinuous P2Y12 signaling, which makes RAP1-dependent platelet 
CalDAG-GEFI–independent RAP1 activation pathway controlled 
by P2Y12 signaling. To test these hypotheses and to circumvent 
the severe thrombocytopenia observed in Rasa3 mutant mice, we 
primarily used Caldaggef1–/– Rasa3hlb/hlb platelets to evaluate how 
RASA3 affects agonist-induced platelet activation in vitro and in 
vivo. No significant difference in the expression levels of major 
adhesion receptors (Figure 4A) or RAP1 protein (Figure 4B) was 
observed among WT, Caldaggef1–/–, and Caldaggef1–/– Rasa3hlb/hlb 
platelets. RASA3 protein expression, however, was strongly 
reduced in lysates from Caldaggef1–/– Rasa3hlb/hlb platelets when 
compared with WT or Caldaggef1–/– cells (Figure 4B), confirming 
results obtained with Rasa3hlb/hlb platelets (Figure 2A). Consistent 
with the critical role of CalDAG-GEFI in platelet signaling (16–18, 
24), both Caldaggef1–/– and Caldaggef1–/– Rasa3hlb/hlb platelets exhib-
ited impaired αIIbβ3 activation in response to cellular stimulation 
(Figure 4C). Agonist-induced activation of αIIbβ3, however, was 
significantly increased in Caldaggef1–/– Rasa3hlb/hlb platelets when 
compared with that in Caldaggef1–/– controls. In addition, agonist 
stimulation of Caldaggef1–/– Rasa3hlb/hlb platelets led to a stronger 
aggregation response (Figure 4D, Figure 5A, and Supplemental 
Figure 9) and increased RAP1 activation (Figure 5B) when com-
pared with Caldaggef1–/– controls.
Figure 2. Platelet preactivation and clearance in Rasa3hlb/hlb mice. (A) RASA3 and RAP1 protein levels evaluated by immunoblotting in lysates of Rasa3+/+ 
and Rasa3hlb/hlb platelets (representative of 3 independent experiments). Peripheral platelet count in Rasa3+/+ (n = 23) and Rasa3hlb/hlb (n = 18) mice. (B) 
Rasa3hlb/hlb platelets circulate in a preactivated state. RAP1 (representative of 3 experiments) and integrin αIIbβ3 activation (n = 5) in unstimulated (none) 
or ADP-activated (10 μM) platelets isolated from Rasa3+/+ or Rasa3hlb/hlb mice. (C) Higher percentage of thiazole orange–positive reticulated platelets in 
Rasa3hlb/hlb blood when compared with Rasa3+/+ blood (n = 6). (D) Decreased life span of Rasa3hlb/hlb platelets. Whole blood samples were obtained from 
Rasa3+/+ and Rasa3hlb/hlb mice at the indicated time points after injection of Alexa Fluor 488–labeled antibodies to GPIX, and the fraction of labeled to 
unlabeled platelets was determined (n = 6). (E) Thrombocytopenia in Rasa3hlb/hlb mice is caused by a defect in the hematopoietic system. Peripheral plate-
let count in lethally irradiated WT mice reconstituted with bone marrow cells from Rasa3+/+ or Rasa3hlb/hlb mice (n = 6). (F and G) Significantly increased 
numbers of mature, acetylcholinesterase-positive megakaryocytes were observed in the (F) spleens and (G) bone marrow of Rasa3hlb/hlb mice. (H) Normal 
colony-forming ability (CFU) of megakaryocyte (Mk) and nonmegakaryocyte progenitors in bone marrow cells (BMC) isolated from Rasa3hlb/hlb mice (n = 6). 
(I) Normal proplatelet (PP) formation in Rasa3hlb/hlb megakaryocytes when compared with controls. Quantification of the percentage of megakaryocytes 
forming proplatelets in culture and representative images. Scale bar: 50 μm (n = 6). *P < 0.05, **P < 0.01, ***P < 0.0001, 2-tailed Student’s t test.
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αIIbβ3 activation in these cells. We also studied the aggregation 
response of Caldaggef1+/– Rasa3hlb/hlb platelets and control platelets 
to ADP and to an agonist specific for the Gαq-coupled receptor for 
ADP, P2Y1 (MRS-2365) (43). As shown previously, ADP-induced 
platelet aggregation requires concomitant signaling by both the 
Gαq-coupled receptor P2Y1 and the Gαi-coupled receptor P2Y12 
(44). Consistently, Caldaggef1+/– Rasa3+/hlb control platelets aggre-
gated in response to stimulation with ADP but not the P2Y1-spe-
cific agonist MRS-2365 (Figure 5F). Aggregation was restored, 
however, when platelets were stimulated with MRS-2365 and 
epinephrine, a platelet agonist that stimulates a Gαi signaling 
response similar to that of P2Y12 (44). Importantly, aggregation of 
Caldaggef1+/– Rasa3hlb/hlb platelets required only MRS-2365, further 
demonstrating that impaired RASA3 function constitutes a state of 
continuous P2Y12 signaling.
Platelet accumulation and hemostatic plug formation at sites of 
vascular injury are insensitive to P2Y12 inhibitors in Caldaggef1–/– 
Rasa3hlb/hlb mice. To validate our findings in vivo, we studied 
the hemostatic response in WT, Caldaggef1–/–, and Caldaggef1–/– 
Rasa3hlb/hlb mice, i.e., mice with similar peripheral platelet counts. 
activation independent of feedback activation by ADP. This latter 
conclusion was confirmed when we studied integrin activation 
kinetics in platelets using a flow cytometry–based assay. As shown 
in Figure 5C, agonist-induced αIIbβ3 activation in Caldaggef1–/– 
Rasa3hlb/hlb platelets was more robust than that in Caldaggef1–/– con-
trols. Furthermore, αIIbβ3 activation in Caldaggef1–/– platelets was 
modulated by the presence of an exogenous P2Y12 agonist (ADP) 
or P2Y12 inhibitor (2-methylthio-AMP triethylammonium salt 
hydrate [2-MeSAMP]) (Figure 5D), while no such modulation was 
observed in Caldaggef1–/– Rasa3hlb/hlb cells (Figure 5D). Consistent 
with the documented role for Ca2+/CalDAG-GEFI in the rapid acti-
vation of RAP1 (17, 24), αIIbβ3 activation in Caldaggef1–/– Rasa3hlb/hlb 
platelets occurred with a delay when compared with that in WT 
controls (Figure 5C, blue box).
Due to their marked thrombocytopenia, we were unable to 
perform comprehensive aggregation or RAP1 activation studies 
with platelets from Rasa3hlb/hlb mice. However, our flow cytometry 
studies demonstrated that αIIbβ3 activation in Rasa3hlb/hlb plate-
lets was not significantly reduced in the presence of an inhibi-
tor of P2Y12 (Figure 5E), even though there was a trend to lower 
Table 1. Peripheral blood cell counts and spleen weights in Rasa3hlb mutant adult male mice carrying the H794L mutation in all cell 
types
Genotype (Rasa3) wbc (×103/ml) PLT (×103/ml) MPV (fL) rbc (×106/ml) Hct (%) Spleen weight (% of BW)
+/+ 9.2 ± 1.9 1,039 ± 137 4.7 ± 0.04 10.3 ± 0.4 48.5 ± 1.7 0.56 ± 0.21
+/hlb 7.6 ± 0.9A 1,114 ± 161 6.6 ± 0.13A 9.7 ± 1.5 47.6 ± 8.1 0.58 ± 0.11
hlb/hlb 3.8 ± 0.6B 29 ± 18B 8.7 ± 0.35B 9.5 ± 1.0 46.1 ± 2.9 0.84 ± 0.28B
Hct, hematocrit; MPV, mean platelet volume; PLT, platelet. AP < 0.001, BP < 0.0001.
Figure 3. Platelet number and life span in Rasa3hlb/hlb mice 
are normalized by reducing CalDAG-GEFI expression. (A and 
B) Deletion of CalDAG-GEFI restores the peripheral platelet 
count and platelet life span in Rasa3hlb/hlb mice. (A) Whole 
blood samples were obtained from controls and Caldaggef1+/+ 
Rasa3hlb/hlb, Caldaggef1+/– Rasa3hlb/hlb, and Caldaggef1–/– 
Rasa3hlb/hlb mice, and platelet counts per ml blood were 
determined (n = 6). (B) Whole blood samples were obtained 
from WT, Caldaggef1+/+ Rasa3hlb/hlb, Caldaggef1+/– Rasa3hlb/hlb, 
and Caldaggef1–/– Rasa3hlb/hlb mice at the indicated time points 
after injection of anti-GPIX Alexa Fluor 488, and the fraction 
of labeled to unlabeled platelets was determined (n = 6).  
*P < 0.05, ***P < 0.0001, 2-way ANOVA with Bonferroni 
post-test. (C) Reduced platelet half-life in Rasa3hlb/hlb mice is 
caused by a defect that is intrinsic to platelets. The bar graph 
shows the survival of Caldaggef1+/– Rasa3+/+ or Caldaggef1+/– 
Rasa3hlb/hlb platelets after transfusion into WT recipient mice 
(n = 6). ***P < 0.0001, 2-tailed Student’s t test.
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Hemostatic plug formation was assessed in mice treated or not 
with the P2Y12 inhibitor clopidogrel bisulfate (Figure 6 and Sup-
plemental Videos 1–6). Using a laser ablation system, an injury to 
the endothelium with a diameter of approximately 50 to 100 μm 
was generated in the saphenous vein, and platelet accumulation 
(Figure 6, A and B) and time to cessation of blood loss (Figure 6C) 
were quantified. In agreement with our in vitro data, we observed 
significantly increased platelet adhesion and a shortened bleeding 
time in Caldaggef1–/– Rasa3hlb/hlb mice when compared with those of 
Caldaggef1–/– controls. However, platelet accumulation and hemo-
static plug formation were delayed in Caldaggef1–/– Rasa3hlb/hlb mice 
compared with those in WT controls, consistent with the docu-
mented role for CalDAG-GEFI in the rapid activation of platelet 
integrins (Figure 5C and ref. 17). In spite of their slow adhesion 
kinetics, more Caldaggef1–/– Rasa3hlb/hlb platelets than WT platelets 
accumulated over time at the site of injury, as platelet adhesion 
was more stable in Caldaggef1–/– Rasa3hlb/hlb mice compared with 
that observed in WT mice (45).
Clopidogrel bisulfate (Plavix) is one of the most widely used 
antiplatelet drugs (46). We demonstrated recently that adminis-
tration of clopidogrel bisulfate significantly reduces the stability 
of thrombi in injured arterioles and venules of WT mice, while it 
virtually abolishes thrombus formation in Caldaggef1–/– mice (17). 
Here, we confirmed these findings in the laser injury hemosta-
sis model (Figure 6). Consistent with our in vitro data, however, 
administration of clopidogrel bisulfate did not significantly impair 
platelet accumulation (Figure 6, A and B) or hemostasis (Figure 
6C) at sites of laser injury in Caldaggef1–/– Rasa3hlb/hlb mice. Together, 
our findings strongly suggest that P2Y12 signaling downregulates 
RASA3 activity during thrombus formation.
Discussion
Based on our results, we propose the following model for the 
regulation of RAP1 signaling (Figure 7). In circulating platelets, 
CalDAG-GEFI activity is low and RASA3 is active in the plasma 
membrane (PM) (47–49) to limit RAP1 activation. At sites of 
vascular injury, platelets are activated via engagement of ITAM 
receptors and/or GPCRs. Activation of PLC is a downstream sig-
naling event common to most of these receptors. Activated PLC 
leads to the generation of two important second messengers: 
Ca2+ and diacylglycerol (DAG). Ca2+ activates CalDAG-GEFI, 
which mediates rapid nucleotide exchange on RAP1. Activated 
RAP1-GTP in turn promotes various platelet responses, includ-
ing TALIN-dependent αIIbβ3 activation (50). CalDAG-GEFI 
signaling, however, is reversible and returns to baseline when 
cytosolic Ca2+ levels normalize. DAG is critical for the activa-
tion of PKC, which affects RAP1 signaling in two ways. First, 
PKC signaling can induce nucleotide exchange in RAP1 by a 
CalDAG-GEFI-independent mechanism. In addition, PKC sig-
naling is critical for the release of ADP-containing storage gran-
ules from activated platelets. ADP, via binding to P2Y12, induces 
the activation of PI3K, which leads to decreased RASA3 function 
Figure 4. RASA3 deletion leads to increased 
αIIbβ3 activation in stimulated platelets. (A) 
Normal membrane expression of glycoprotein 
receptors in WT, Caldaggef1–/– Rasa3+/+, or 
Caldaggef1–/– Rasa3hlb/hlb platelets. Diluted 
whole blood was stained for 10 minutes with 
fluorophore-labeled antibodies (2 μg/ml) to 
the indicated antigens and analyzed by flow 
cytometry (n = 6). (B) RASA3 and RAP1 protein 
level evaluated by immunoblotting in lysates 
of WT, Caldaggef1–/– Rasa3+/+, or Caldaggef1–/– 
Rasa3hlb/hlb platelets. Results are represen-
tative of 3 independent experiments. (C) 
Increased integrin αIIbβ3 activation (JON/A-PE 
binding) in activated Caldaggef1–/– Rasa3hlb/hlb 
platelets when compared with Caldaggef1–/– 
controls. Platelets were stimulated for 10 
minutes with increasing concentrations 
of Par4-activating peptide (Par4p) or the 
GPVI-specific agonist convulxin (Cvx), stained 
with JON/A-PE, and immediately analyzed 
by flow cytometry. MFI, mean fluorescence 
intensity. *P < 0.05, ***P < 0.0001, 2-way 
ANOVA with Bonferroni post-test (n = 6, 3 
independent experiments). (D) Aggrega-
tion response of washed WT, Caldaggef1–/– 
Rasa3+/+, or Caldaggef1–/– Rasa3hlb/hlb platelets 
stimulated with low (left) or high (right) doses 
of collagen, thrombin, or the thromboxane 
analog U46619. Results are representative of 3 
independent experiments.
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and prolonged RAP1 signaling. Inhibitors to P2Y12 prevent the 
inactivation of RASA3, prohibit prolonged RAP1 signaling, and 
destabilize the growing thrombus.
RASA3 is positioned perfectly to prevent unwanted RAP1- 
dependent platelet activation, as it is targeted to the PM of resting 
cells by the interaction of its unique PH/BTK domain with phos-
phatidylinositol 4,5-bisphosphate (PIP2) (47–49). At sites of vascu-
lar injury, however, RASA3 activity in platelets must be reduced to 
allow for the formation of a hemostatic plug. Our studies suggest 
that this process is mediated by PI3K, a family of enzymes capable 
of phosphorylating the 3′ position hydroxyl group of the inositol 
ring of phosphoinositol. Activated PI3K mediates the conversion 
of PIP2 to phosphatidylinositol 3,4,5-trisphosphate (PIP3) and/
or phosphatidylinositol 3,4-biphosphate. Studies by Lova et al. 
demonstrated that stimulation of a Gαi-dependent signaling path-
way leads to sustained RAP1 activation through the action of the 
PI3K product PIP3 but not phosphatidylinositol 3,4-biphosphate 
(28). The remaining question is whether PIP3, which also binds 
the PH/BTK domain of RASA3 with high affinity, affects RASA3 
function by modulating its enzymatic activity and/or the subcellu-
Figure 5. RAP1 and integrin activation in Rasa3 mutant platelets is insensitive to inhibitors of the P2Y12/PI3K signaling pathway. (A) Aggregation of 
WT, Caldaggef1–/–, or Caldaggef1–/– Rasa3hlb/hlb platelets stimulated with 250 μM Par4-activating peptide in the presence or absence or 100 μM 2-MeSAMP 
or 200 nM wortmannin. Aggregation was monitored for 3 minutes. (B) Levels of activated RAP1 (RAP1-GTP) and AKT (phosphorylated AKT [AKT-P]) in WT, 
Caldaggef1–/–, or Caldaggef1–/– Rasa3hlb/hlb platelets stimulated for 3 minutes with Par4p in the presence of vehicle, 2-MeSAMP, or wortmannin. Total RAP1 
and AKT are shown for loading controls. (C) Real-time flow cytometry analysis of αIIbβ3 activation in WT, Caldaggef1–/–, or Caldaggef1–/– Rasa3hlb/hlb plate-
lets stimulated with Par4p. The blue box highlights delayed αIIbβ3 activation in Caldaggef1–/– and Caldaggef1–/– Rasa3hlb/hlb platelets. (D) Effect of ADP or 
2-MeSAMP on Par4p-induced αIIbβ3 activation kinetics in Caldaggef1–/– Rasa3+/+ or Caldaggef1–/– Rasa3hlb/hlb platelets. (E) Effect of P2Y12 inhibition on αIIbβ3 
activation in Rasa3hlb/hlb platelets stimulated for 10 minutes with the indicated concentrations of Par4p. Data represent MFI ± SD in activated blood samples 
after subtraction of MFI measured in nonactivated cells. ***P < 0.0001, 2-way ANOVA with Bonferroni post-test (n = 6). (F) Aggregation of Caldaggef1+/– 
Rasa3+/hlb or Caldaggef1+/– Rasa3hlb/hlb platelets (in PRP at 1.5 × 108 platelets/ml) stimulated with 3 μM ADP, 0.1 μM MRS-2365 (P2Y1 agonists), or MRS-2365 
plus 1 μM epinephrine (α2A-R agonist). Results in A–D and F are representative of 4 independent experiments.
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to proliferate in vitro. Similar findings were described recently for 
chimeric mice expressing a catalytically inactive mutant of RASA3 
in blood cells only (34). However, Molina-Ortiz et al. also provided 
ex vivo evidence suggesting that impaired function of RASA3 leads 
to thrombocytopenia in mice due to impaired ability of megakary-
ocytes to form proplatelets (34). Using a similar ex vivo assay, we 
did not observe a defect in proplatelet formation for megakaryo-
cytes isolated from Rasa3hlb/hlb mice. One potential explanation 
for these discrepant results derives from the fact that the RASA3 
protein level is markedly reduced in Rasa3hlb/hlb mice, while the 
deletion of the catalytic domain results in the expression of a 
truncated RASA3 protein that may affect megakaryocyte function 
independent of its GAP activity. While we were unable to detect 
a defect in platelet production, we provided strong evidence for 
increased platelet turnover in Rasa3hlb/hlb mice. First, the life span 
of circulating platelets was dramatically shortened in Rasa3hlb/hlb 
mice. Our studies further demonstrated that the decreased life 
span is a defect that is intrinsic to the platelet, as we observed 
increased turnover for endogenous platelets in Rasa3hlb/hlb mice 
as well as for Rasa3hlb/hlb platelets transfused into WT recipient 
mice. Importantly, a reduction in the expression of the RAP-GEF, 
CalDAG-GEFI, significantly increased both the platelet life span 
and the peripheral platelet count in Rasa3 mutant mice. Together, 
these studies suggest that RASA3 is required to protect circulat-
lar localization of RASA3. Answering this question, however, has 
proven to be extremely difficult, even in heterologous cell systems 
(35, 48). Adding to the complexity, recent findings suggest that 
segregation of PIP2 and PIP3 into distinct nanoscale regions in the 
PM (51) could be another mechanism for regulating the function 
of RASA3 in resting and in activated platelets.
Our findings that Caldaggef1–/– Rasa3hlb/hlb platelets show no 
signs of RAP1 activation unless stimulated with agonist further 
demonstrate that RAP1 activation in the absence of CalDAG-
GEFI requires RASA3 inactivation and a signaling event that leads 
to increased nucleotide exchange in the GTPase. Our work (18, 
23) and that of others (21) suggest that this CalDAG-GEFI-inde-
pendent mechanism is mediated by PKC, as aggregation in the 
absence of functional CalDAG-GEFI could be induced with an 
agonist for PKC. Downstream of PKC, the nucleotide exchange 
could be facilitated by a different RAP-GEF, such as CalDAG- 
GEFIII, PDZ-GEF1/2, or C3G, which are expressed at low levels 
in platelets (29, 31, 52). Alternatively, nucleotide exchange may be 
regulated by posttranslational modifications of RAP1, such as oxi-
dation (53), ubiquitination (54), or phosphorylation (55).
Our studies also identified a significant expansion of megakary-
ocytes in the spleens and the bone marrow of Rasa3 mutant mice. 
Rasa3hlb/hlb megakaryocytes exhibited largely normal morphology 
and ultrastructure, and we did not observe a defect in their ability 
Figure 6. Hemostatic plug formation in Rasa3hlb/hlb mice is insensitive to P2Y12 inhibitors. Intravital microscopy studies to monitor hemostatic plug 
formation after laser injury to the saphenous vein in WT (also see Supplemental Videos 1 and 4), Caldaggef1–/– (also see Supplemental Videos 2 and 5), and 
Caldaggef1–/– Rasa3hlb/hlb mice (also see Supplemental Videos 3 and 6). Where indicated, mice were treated with clopidogrel bisulfate 24 and 3 hours prior 
to the experiment at a dosage of 75 mg/kg bodyweight to inhibit signaling via the platelet P2Y12 receptor. Prior to laser injury, animals were injected with 
Alexa Fluor 488–labeled antibodies to GPIX, a receptor expressed exclusively on the platelet surface. (A) Representative images taken 30 seconds and 240 
seconds after laser injury (except where indicated by an asterisk). Arrows highlight blood loss at the site of injury. Scale bar: 50 μm. (B) Sum fluorescence 
intensity ± SEM recorded at the site of injury over time in WT, Caldaggef1–/–, and Caldaggef1–/– Rasa3hlb/hlb mice (n = 8–19). (C) Time to stable occlusion (no 
leakage of blood for more than 60 seconds) of the vascular lesion in WT (circles), Caldaggef1–/– (triangles), and Caldaggef1–/– Rasa3hlb/hlb (squares) mice. 
White symbols indicate mice treated with clopidogrel bisulfate. Dotted line represents the time point when recordings were stopped. *P < 0.05,  
***P < 0.0001, 2-way ANOVA with Bonferroni post-test.
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more intact ultrastructure than those from Rasa3scat/scat 
animals correlates well with the degree of thrombo-
cytopenia observed in these mice. At this point, we 
have only limited information on how Rasa3 mutant 
platelets are cleared from circulation. Our studies 
suggest that clearance occurs mainly in the spleen 
and liver, consistent with the removal of platelets by 
phagocytic cells of the reticuloendothelial system (4). 
Interestingly, however, platelet counts did not recover 
in splenectomized Rasa3hlb/hlb mice, suggesting that 
impaired RASA3 function may cause platelet clear-
ance via more than one mechanism, maybe involving 
the formation and clearance of microaggregates.
In addition to the severe thrombocytopenia, both 
Rasa3scat/scat and Rasa3hlb/hlb mice exhibited a marked 
reduction in the peripheral lymphocyte count. Pre-
liminary results obtained with the few surviving Rasa3 
knockout mice confirmed these observations (data 
not shown). Lymphocytes express significant amounts 
of RAS (61), and the duration and subcellular local-
ization of RAS/ERK signaling was shown to dictate 
whether lymphocytes proliferate or differentiate (62). 
This is in contrast to platelets, in which physiological 
relevance for the low levels (63) of expressed RAS iso-
forms has not been documented yet (64). RAP1 is also 
expressed in lymphocytes and regulates the homing of 
these cells to lymph nodes (65). It will be interesting 
to see whether mutations in RASA3 affect peripheral 
lymphocyte counts by modulating the activity of RAS, 
RAP, or both. While Rasa3scat/scat mice also exhibit a 
profound anemia (33), the defect in rbc is very mild 
in Rasa3hlb/hlb mice (L.L. Peters, unpublished observa-
tions). Factors that may contribute to this phenotypic 
difference between the Rasa3scat and Rasa3hlb mutant 
models likely include the difference in the mutant 
allele and the genetic background of these mutant 
strains (BALB/cByJ-scat; C57BL/6J-hlb381). Furthermore, condi-
tional deletion of Rasa3 will be required to identify whether any 
changes documented for lymphocytes or erythrocytes in Rasa3 
mutant mice are explained solely by defects intrinsic to these cell 
types or whether some of the phenotype is secondary to the marked 
developmental defects caused by the severe thrombocytopenia.
To date, no patients with impaired RASA3 expression or function 
have been described, and one has to be careful when extrapolating 
findings in mice to humans. However, for the following reasons, 
we believe that a similar RASA3-dependent mechanism controls 
RAP1-dependent platelet activation in humans. First, transcrip-
tome and proteome analysis of human platelets identified RASA3 as 
the predominant RAP-GAP in these cells (30–32). Second, we and 
others identified two independent yet synergistic pathways critical 
to RAP1 activation in mouse and human platelets (11, 21, 23, 27). 
Fast but reversible RAP1 activation is dependent on calcium and 
CalDAG-GEFI, while sustained RAP1 activation requires signaling 
by P2Y12 and PI3K (11, 13, 17, 24). Significantly, the importance of a 
CalDAG-GEFI-dependent and -independent pathway to RAP1 acti-
vation was confirmed recently in patients with impaired CalDAG-
GEFI function (21). Last, a recent genome-wide association study 
ing platelets from CalDAG-GEFI/RAP1-mediated activation and 
clearance. Consistent with this, Grosse et al. recently described 
a very similar platelet clearance phenotype for mice express-
ing a gain-of-function mutant of stromal interaction molecule 1 
(Stim1Sax) (56). STIM1 is an important regulator of store-operated 
calcium entry (SOCE), the predominant mechanism in the regu-
lation of calcium influx into platelets (57). Platelets from Stim1+/Sax 
mice exhibit constitutive SOCE, preactivation, and markedly 
reduced life span in circulation. Thus, both elevation of cytosolic 
Ca2+, a critical regulatory step in the activation of CalDAG-GEFI 
(18, 24, 58), and inactivation of RASA3 lead to platelet activation 
and markedly increased platelet turnover.
As indicated by the significantly increased volume of circu-
lating platelets in both Stim1+/Sax and Rasa3hlb/hlb mice, the rapid 
turnover of platelets likely affects the process of proplatelet for-
mation from maturing megakaryocytes. This has previously been 
demonstrated for megakaryocytes in mice that were rendered 
thrombocytopenic by infusion of antiplatelet serum or neuramin-
idase (59, 60). In both cases, induction of severe thrombocytope-
nia was followed by an increase in sectional areas of platelets. Our 
observation that megakaryocytes from Rasa3hlb/hlb mice show a 
Figure 7. Schematic illustrating the regulation of RAP1 signaling in platelets. RAP1 
activation in platelets is tightly controlled by the antagonistic balance between the calcium-
sensitive RAP-GEF, CalDAG-GEFI, and the RAP-GAP, RASA3. In quiescent platelets, RASA3 
restrains unwanted CalDAG-GEFI/RAP1 signaling to ensure platelet homeostasis. At sites 
of vascular injury, platelet stimulation through ITAM-coupled (collagen receptor GPVI, podo-
planin receptor CLEC-2, and IgG receptor FcγRIIA) and G protein–coupled (thrombin receptors 
PAR1/3/4, ADP receptor P2Y1, and TxA2 receptors) receptors leads to the activation of PLCγ2 
and PLCβ2/3, respectively. PLCs convert PIP2 to DAG and inositol 1,4,5-trisphosphate (IP3). 
IP3 mediates Ca2+ store release and a rise in the cytosolic Ca2+ concentration, which triggers 
rapid CalDAG-GEFI-dependent RAP1 activation. DAG leads to PKC activation, which con-
tributes to nucleotide exchange on RAP1 and the release of platelet granules. CalDAG-GEFI 
signaling eventually subsides and RASA3 must be inactivated in order to maintain RAP1 in 
an activated state. RASA3 inactivation depends on PI3 kinase signaling, which in platelets 
is under the control of Gαi-coupled receptors, such as P2Y12 (ADP) or α2A-R (epinephrine). 
Both rapid and sustained RAP1 signaling are critical for integrin inside-out activation and the 
formation of a hemostatic plug. P2Y12 inhibitors prevent the inactivation of RASA3 and thus 
destabilize the growing thrombus.
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dosage of 75 mg/kg bodyweight. P2Y12 inhibition was confirmed by 
standard aggregometry (impaired response to ADP, data not shown). 
Treatment with clopidogrel bisulfate did not affect platelet counts or 
counts of other blood cells (data not shown).
Peripheral cell counts
Whole blood was collected from the retro-orbital plexus into EDTA-
containing 1.5 ml microtubes. Complete blood counts were deter-
mined using an automated hematology analyzer (Advia 120 Multispe-
cies Hematology Analyzer, Bayer Diagnostics).
Bone marrow cell transplantation
Bone marrow cells were harvested from the tibias and femurs 
of adult donor mice. A total of 2 × 106 cells were transplanted by 
retro-orbital injection (100 ml per mouse) into (8- to 10-week-old) 
recipient animals conditioned with a lethal dose of 2 × 600 cGy total 
body irradiation.
Platelet preparation
Blood was drawn with heparin-coated capillaries (VWR) from the 
retro-orbital plexus into tubes containing low-molecular-weight 
Lovenox (enoxaparin sodium, Sanofi-Aventis). Platelet-rich plasma 
(PRP) was obtained by centrifugation at 100 g for 5 minutes. PRP was 
centrifuged at 700 g for 5 minutes at room temperature in the pres-
ence of 5 μM prostacyclin (PGI2) from Sigma-Aldrich. After 2 washing 
steps, pelleted platelets were resuspended in modified Tyrode’s buffer 
(137 mM NaCl, 0.3 mM Na2HPO4, 2 mM KCl, 12 mM NaHCO3, 5 mM 
N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid, 5 mM glucose, 
pH 7.3) containing 1 mM CaCl2. PRP from Rasa3hlb/hlb and Rasa3+/+ con-
trol mice was obtained by centrifugation of whole blood with 2 mM 
EDTA at 100 g. Platelets were washed with modified Tyrode’s buffer 
containing 2 mM EDTA and PGI2, centrifuged at 700 g using a swing-
ing bucket rotor, and, ultimately, resuspended in modified Tyrode’s 
buffer containing 1 mM CaCl2.
Flow cytometry
Platelet count. 8- to 10-week-old mice were bled retro-orbitally (50 μl), 
and platelets were labeled for 10 minutes with 2 μg/ml Alexa Fluor 
488–labeled antibody to GPIX (clone Xia.B4, Emfret Analytics). Sam-
ples were diluted with PBS, and the number of GPIX-positive events 
per volume was determined with a BD Accuri C6 Flow Cytometer.
Reticulated (young) platelet count. Blood was drawn from the 
retro-orbital plexus (50 μl) and diluted in rbc lysis buffer (10 mM 
KHCO3, 150 mM NH4Cl, 0.1 mM EDTA pH 8.0). After rbc lysis, plate-
lets were washed with PBS, resuspended in PBS with 2% fetal bovine 
serum, and labeled with an α-CD41 antibody (clone MWReg30, BD 
Bioscience) conjugated to phycoerythrin (PE). Cells were washed in 
PBS and resuspended in Retic Count solution (thiazole-orange dye) 
(Becton Dickinson) (70). Platelets were gated according to the PE 
staining and analyzed for thiazole-orange staining.
Platelet life span. Platelets were labeled in vivo by a single intra-
venous injection of 5 μg Alexa Fluor 488–conjugated α-GPIX anti-
body (clone Xia.B4, Emfret Analytics) in 100 μl PBS at t = 0. Whole 
blood (50 μl) was drawn every 24 hours, diluted, and incubated with a 
PE-conjugated antibody to GPIbα (clone Xia.G5, Emfret Analytics) for 
10 minutes at room temperature. The ratio of Alexa Fluor 488–positive 
platelets to PE-positive platelets was determined.
identified a single nucleotide polymorphism that is in linkage with 
RASA3 and correlates with mean platelet volume variations in 
humans (66). Similar to these findings, we observed a significant 
increase in mean platelet volume in Rasa3hlb mice (Table 1).
The P2Y12 receptor is the target of clinically successful anti-
platelet drugs, such as ticagrelor, clopidogrel bisulfate, or prasug-
rel (46). Based on our results, we propose that P2Y12 signaling is 
critical for the inactivation of RASA3 in activated platelets and 
that P2Y12 inhibitors protect from thrombosis primarily due to 
their effect on the RASA3/RAP1 signaling module. These find-
ings may have important implications for the development of 
safer antiplatelet therapies. For example, an antidote to P2Y12 
inhibitors would greatly improve the safety of such therapies, as 
it could be used to manage bleeding complications in patients 
taking these drugs. Our work suggests inhibition of RASA3 as 
one such approach to antagonize P2Y12 inhibitors, although such 
a therapy would likely need to be carefully monitored to avoid 
complications, such as thrombocytopenia or excessive platelet 
reactivity. Our findings may also explain some of the interindi-
vidual variability in ADP-induced integrin activation, observed 
both in the presence and absence of P2Y12 inhibitors (67). Based 
on our studies, we suggest that variations in the expression levels 
of CalDAG-GEFI and RASA3, i.e., the antagonistic balance of a 
critical GEF and GAP for RAP1, may contribute to this variability 
in platelet reactivity.
In summary, we have identified the RAP-GAP RASA3 as a 
critical negative regulator of platelet activation. RASA3 main-
tains circulating platelets in a quiescent state as it antagonizes 
low-level RAP1 activation by the RAP-GEF, CalDAG-GEFI. At 
sites of vascular injury, continuous signaling through P2Y12 and 
PI3K is necessary to ensure RASA3 inhibition, sustained RAP1/
integrin activation, and the formation of a stable hemostatic plug. 
Thus, our studies suggest that the antagonistic balance between 
CalDAG-GEFI and RASA3 is critical for platelet homeostasis and 
vascular hemostasis. Our findings may lead to improved diagnosis 
and treatment of platelet-related disorders.
Methods
Mice
Rasa3scat/scat (Rasa3G125V/G125V) (33), Caldaggef1–/– (18), and Pf4-Cre+ (68) 
mice have been described previously. Rasa3hlb/hlb (Rasa3H794L/H794L) mice 
were derived from a N-ethyl-N-nitrosourea mutagenesis screen per-
formed at The Jackson laboratory, as described in detail previously 
(69). For the generation of Rasa3 knockout mice, a targeting vector was 
obtained from the KOMP-CSD (Knockout Mouse Project–CHORI/
Sanger/University of California, Davis) consortium, and targeting of 
C57BL/6 ES cells was performed by the Animal Models Core at the 
University of North Carolina at Chapel Hill. Megakaryocyte-specific 
Rasa3 knockout mice were generated by crossing Rasa3fl/fl mice with 
Pf4-Cre+ mice (for details see Supplemental Figure 1). The following 
primers were used for the genotyping of conventional and condi-
tional knockout mice: FlpA 5′-AAAACACACTGAGGTTCAGACAC-
GCTCC-3′, FlpS 5′-GTCATCCATGGGTTTCCTAAGCACTTCC-3′, 
and Neo3-30 5′-CGCATCGCCTTCTATCGCCTTCTTGACGA-3′.
Where indicated, mice were treated with clopidogrel bisulfate 
(Plavix, Sanofi-Aventis) 24 and 3 hours prior to the experiment at a 
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Histology, immunohistochemistry, and electron microscopy
Megakaryocytes in spleens and bones of Rasa3+/+ and Rasa3hlb/hlb mice. 
Euthanized mice were weighed, and tissues were dissected for 
weighing and/or analysis. Spleen and hind leg tissue from 3 control 
and mutant mice were fixed in Bouin’s solution (Sigma-Aldrich). Hind 
legs were left in Bouin’s solution for 3 days in order to decalcify bones. 
Tissues were paraffin-embedded, sectioned at 3 to 5 μm, and stained 
with H&E for pathological analysis using standard techniques. For 
staining of acetylcholinesterase activity, unfixed spleens and femurs 
were frozen in OCT embedding compound (Tissue-Tek), cryostat 
sectioned at 10 μm, and stained as previously described (74, 75). For 
transmission electron microscopy, bone marrow was flushed from 
both femurs using PBS containing fetal calf serum and EDTA. Packed 
bone marrow cells were washed with the same PBS solution and 
fixed overnight in 2% glutaraldehyde/2% paraformaldehyde in 0.1 M 
cacodylate buffer (pH 7.4). Bone marrow cell pellets were embedded 
in agar, sectioned, and postfixed in osmium using standard tech-
niques. A JEOL 100CXII transmission electron microscope was used 
for examination and image capturing.
Rasa3 knockout embryos. Pregnant animals were dissected at ges-
tational day E15.5 (Rasa3+/– × Rasa3+/–) or E17.5 (Rasa3+/flPF4-Cre+ × 
Rasa3+/flPF4-Cre+), and embryos were imaged using a Leica MZ16FA 
dissecting stereoscope. For some embryos, blood was collected by 
placing the entire embryo in 100 μl PBS containing heparin, cutting the 
umbilical cord, and gently palpating the embryo’s abdomen. Embryos 
were paraffin embedded, and H&E-stained sections were imaged 
using an Olympus BX61 with a QImaging RETIGA 4000R camera 
with Volocity software (Improvision, PerkinElmer). For immunohis-
tochemistry, embryo sections were deparaffinized, hydrated, perme-
abilized, and blocked with 5% normal donkey serum. Slides were then 
stained with primary antibody, polyclonal rabbit anti-mouse LYVE-1 
(catalog no. 70R-LR003, Fitzgerald Industries International), over-
night at room temperature. Sections were rinsed, blocked, and incu-
bated with donkey anti-rabbit Alexa Fluor 488 (catalog no. 711-545-
152, Jackson ImmunoResearch) and DAPI (Sigma-Aldrich) in the dark 
for 90 minutes at room temperature. Images were acquired on a Nikon 
E800 microscope with a Hammamatsu camera with Metamorph soft-
ware (Molecular Devices Corp.).
Clearance of Rasa3 mutant platelets
Radiolabeling of antibody. The anti-GPXI antibody (clone Xia.B4, 
Emfret Analytics) was washed twice with borate buffer (pH 9.0) 
containing 50 mM EDTA to remove trace metals. The antibody was 
washed an additional 5 times with borate buffer to remove excess 
EDTA. The final antibody was concentrated to 2 mg/ml (100 μl) and 
mixed with the bifunctional metal chelator p-SCN-Bn-NOTA (Mac-
rocyclics) for 24 hours at 4°C. The reaction mixture was placed into a 
fresh Amicon filter (30,000 NMWL) and excess chelator was removed 
by 5 subsequent washes with 0.1 M ammonium acetate. 37 MBq (1 
mCi) of copper-64 (copper-64 [t1/2 = 12.7 hour] was purchased from 
Mallinckrodt Institute of Radiology at Washington University School 
of Medicine as a copper chloride solution [in 0.1 M HCl] and was neu-
tralized with 0.1 M ammonia acetate buffer upon arrival) was added 
to the antibody and allowed to chelate over 20 minutes at room tem-
perature. This reaction gave a radiochemical yield of 95%. The reac-
tion mixture was placed into a fresh Amicon filter (30,000 NMWL) 
and washed twice with PBS containing EDTA (50 mM) followed by 
Surface receptors. 2 × 106 platelets in diluted whole blood (modi-
fied Tyrode’s buffer) were stained for 10 minutes with 2 μg/ml fluo-
rophore-conjugated antibodies to the indicated platelet surface glyco-
proteins and immediately analyzed by flow cytometry. Antibodies for 
GPIX (clone Xia.B4), GPIbα (clone Xia.G5), GPVI (clone JAQ1), integ-
rin α2 (clone Sam.G4), and IgG controls were purchased from Emfret 
Analytics. FITC-labeled CLEC-2 antibody was provided by Bernhard 
Nieswandt (University Clinic of Wuerzburg and Rudolf Virchow Cen-
ter, Wuerzburg, Germany).
αIIbβ3 Activation and α-granule secretion. 2 × 106 platelets in 
diluted whole blood (modified Tyrode’s buffer containing 1 mM 
CaCl2) were activated with ADP (Sigma-Aldrich), convulxin (pur-
chased from Kenneth Clemetson, Theodor Kocher Institute, Univer-
sity of Berne, Bern, Switzerland), or PAR4-activating peptide (Par4p; 
GL Biochem Inc.) in the presence of 2 μg/ml JON/A-PE, an antibody 
directed toward the activated form of murine αIIbβ3 (Emfret Ana-
lytics) (71), and 2 μg/ml α-P-selectin-FITC (clone RB40.34, BD Bio-
sciences). Following 10 minutes of incubation, samples were diluted 
with PBS and analyzed immediately.
Real-time αIIbβ3 activation assay. Washed platelets were diluted 
(1.25 × 107 platelets/ml) in Tyrode’s buffer containing 1 mM CaCl2. 
Where indicated, platelets were incubated for 10 minutes with 100 
μM 2-MeSAMP (BioLog) to inhibit signaling by P2Y12. After estab-
lishing a baseline with unlabeled platelets, JON/A-PE (5 μg/ml) and 
Par4p (600 μM) were added simultaneously in an equal volume of 
modified Tyrode’s buffer to allow efficient mixing. JON/A-PE bind-
ing was recorded continuously for 10 minutes with a BD Accuri C6 
Flow Cytometer (72).
CFU assays for megakaryocyte progenitors
CFU-megakaryocytes were detected in bone marrow using a Mega-
Cult-C Kit, a collagen-based media growth system (Stem Cell Technol-
ogies). The media was supplemented with 50 ng/ml rhTpo, 10 ng/ml 
rmIL-3, 20 ng/ml rhIL-6, and 50 ng/ml rmIL-11. Bone marrow aspi-
rates from 3 Rasa3+/+ and 3 Rasa3hlb/hlb mice, each in 4 technical repli-
cates per mouse, were plated in slide chambers. Slides were incubated 
at 37°C. After 7 days, the slides were dehydrated and fixed in acetone. 
Slides were stained with acetylthiocholine iodide and counterstained 
with Harris’ hematoxylin solution. The slides were then examined 
under an inverted microscope, and colonies containing at least 3 
brown cells were scored.
Differentiation of mouse megakaryocytes
Proplatelet formation was studied in mouse bone marrow–derived 
megakaryocytes as described recently (73). Mice (8 to 10 weeks of 
age) were euthanized, and cells were obtained from the bone mar-
row of femurs and tibias. Cells were homogenized by pipetting, fol-
lowed by passage through a 100-μm filter. The cell population was 
resuspended in 10% fetal bovine serum–supplemented DMEM with 
2 mM l-glutamine, 50 U/ml penicillin/streptomycin, and fibroblast- 
conditioned media containing thrombopoietin. The cells were cul-
tured for 4 days (37°C and 5% CO2), and mature megakaryocytes 
were layered over a BSA gradient. Megakaryocytes were resus-
pended in culture media and placed on immobilized fibrinogen, 
and megakaryocytes with proplatelets were counted. A minimum of 
100 megakaryocytes was analyzed to determine the percentage of 
proplatelet formation.
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antibodies (Li-Cor Biosystems), respectively, and visualized with the 
Odyssey Infrared Imaging System (Li-Cor Biosystems).
Laser-induced injury of the saphenous vein
Mice (8–12 weeks of age) were anesthetized by intraperitoneal injection 
of ketamine (100 mg/kg) and xylazine (10 mg/kg) (Med-Vet Interna-
tional). Alexa Fluor 488–labeled antibodies against GPIX were admin-
istered through retro-orbital injection. The saphenous vein was located, 
and baseline fluorescence was recorded for 30 seconds using a Zeiss Axio 
Examiner Z1 microscope (Intelligent Imaging Innovations) equipped 
with a 20x/1 numerical aperture water immersion objective lens. Injury 
to the endothelium was initiated using an Ablate! photoablation system 
equipped with an attenuable 532-nm pulse laser (Intelligent Imaging 
Innovations), and fluorescence intensity was recorded for 270 seconds. 
Throughout the experiment, constant perfusion drip was maintained on 
the exposed saphenous vein with a physiologic salt solution containing 
132 mmol/l NaCl, 4.7 mmol/l KCl, 1.2 mmol/l MgSO4, 2 mmol/l CaCl2, 
and 18 mmol/l NaHCO3 (pH 7.4), which was bubbled with 5% CO2/95% 
N2 15 minutes prior to the start of the experiment. The physiological 
salt solution was maintained at 37°C via a Sloflo In-line solution heater 
(SF-28) and single channel heater controller (model TC-324B, Warner 
Instruments). All data were recorded and analyzed using Slidebook 5.0 
software (Intelligent Imaging Innovations).
Statistics
Results are reported as mean ± SEM, and statistical significance was 
assessed by 2-tailed Student’s t test, unless indicated otherwise. A P 
value of less than 0.05 was considered significant.
Study approval
Mice were housed in the University of North Carolina at Chapel Hill, 
The Jackson Laboratory, and Case Western Reserve University animal 
facilities. Experimental procedures were approved by the University of 
North Carolina at Chapel Hill, The Jackson Laboratory, and Case West-
ern Reserve University Institutional Animal Care and Use Committees.
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3 washes with PBS. Centrifugal filtration gave radiolabeled antibody 
with >99% radiochemical purity. Radiochemical purity was deter-
mined using size exclusion chromatography on an Agilent 1260 HPLC 
system equipped with a BIO-SEC-5 100Å column (data not shown).
Animal studies. Approximately 3 MBq (~80 μCi) of 64Cu-NOTA 
mAb was incubated with 1.2 × 108 platelets (15 minutes, room temper-
ature). Before injection into mice, platelets were washed and resus-
pended in modified Tyrodes buffer. 4 × 107 Caldaggef1+/– Rasa3hlb/hlb 
platelets or Caldaggef1+/– Rasa3+/+ control platelets were injected into 
C57BL/6 mice (n = 3 per group). Organs and blood were harvested 24 
hours after platelet transfusion. Each tissue was counted for radioac-
tivity using a Capintec CRC-55tW gamma-counter.
Aggregometry
Washed platelets were resuspended at a concentration of 2 × 108 plate-
lets/ml in modified Tyrode’s Buffer containing 0.35% BSA (fraction 
V, Sigma-Aldrich) and 1 mM CaCl2. The experiment was performed 
at 37°C in the presence of 50 μg/ml human fibrinogen type I (Sigma- 
Aldrich) and under stirring conditions (1,200 rpm). Where indicated, 
platelets were incubated for 10 minutes with 100 μM 2-MeSAMP 
(P2Y12 inhibitor) or 200 nM wortmannin (PI3K inhibitor, Cayman 
Chemical). Platelets were stimulated with fibrillar collagen type I 
from Chrono-log, α-thrombin from Enzyme Research Laboratories, 
U46619 from Cayman Chemical, ADP and epinephrine from Sigma- 
Aldrich, Par4p from GL Biochem Inc., and MRS 2365 from Tocris Bio-
science. Light transmission was recorded until it reached a plateau on 
a Chrono-log 4-channel optical aggregation system (Chrono-log).
RAP1 and AKT activation assay
Washed platelets (4 × 108 platelets per sample) were stimulated with 
250 μM Par4p for 3 minutes at 37°C in a standard aggregometer. Reac-
tions were stopped with ice-cold 2x lysis buffer (100 mM Tris/HCl, pH 
7.4, 400 mM NaCl, 5 mM MgCl2, 2% Nonidet P-40, 20% glycerol, and 
protease inhibitor cocktail lacking ethylenediaminetetraacetic acid). 
Cell lysis was completed on ice for 15 minutes. 50 μl of sample was 
immediately solubilized in sample buffer (75 mM Tris/HCl, pH 6.8, 
10% sodium dodecyl sulfate, 5% 2-Mercaptoethanol, 0.004% Bromo-
phenol blue) for the detection of phosphorylated AKT, total AKT, and 
total RAP1 levels (see below). The cell lysates were incubated for 45 
minutes with RalGDS-RBD beads (Millipore) to pull-down RAP1-GTP 
(24). After 3 washing steps the pellets were solubilized in sample buf-
fer for the detection of active RAP1 by immunoblot. Whole cell lysates 
for the detection of RASA3 were obtained by lysing washed platelets in 
ice-cold 2x lysis buffer.
Western blotting
Proteins were separated by SDS–polyacrylamide gel electrophore-
sis on 4%–20% gradient gels and transferred to polyvinylidene fluo-
ride membranes (Millipore). Standard Western blotting procedures 
were used. RAP1 (α-RAP1 clone 121, Santa Cruz Biotechnology) and 
RASA3 (rabbit polyclonal α-mouse RASA3 was generated as described 
recently, ref. 33) proteins were detected using HRP-conjugated sec-
ondary antibodies and visualized with Enhanced Chemiluminescense 
(Pierce). AKT (α-AKT, clone 40D4, Cell Signaling Technology) and 
phospho-AKT (α-phospho-AKT Ser473, catalog no. 9271, Cell Sig-
naling Technology) were detected using IRDye 680–conjugated goat 
anti-mouse and IRDye 800–conjugated goat anti-rabbit secondary 
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